Agora 10-Q 9 Feb 15 2015 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Dec. 26, 2014	Feb. 02, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	ADVANCED PHOTONIX INC,
Document Type	10-Q
Current Fiscal Year End Date	-28
Entity Common Stock, Shares Outstanding		37,381,000
Amendment Flag	FALSE
Entity Central Index Key	869986
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	26-Dec-14
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) (USD $)	Dec. 26, 2014	Mar. 31, 2014
Current assets:
Cash and cash equivalents	$110,000	$120,000
Receivables, net	3,814,000	5,085,000
Inventories	4,987,000	4,749,000
Prepaid expenses and other current assets	725,000	444,000
Total current assets	9,636,000	10,398,000
Equipment and leasehold improvements, net	1,769,000	2,144,000
Goodwill	4,579,000	4,579,000
Intangibles and patents, net	2,678,000	2,942,000
Other assets	160,000	138,000
Total Assets	18,822,000	20,201,000
Current liabilities:
Accounts payable	1,580,000	2,661,000
Accrued compensation	790,000	701,000
Accrued subcontracting costs	226,000	344,000
Other accrued expenses	713,000	1,108,000
Current portion of long-term debt--PFG	714,000	714,000
Current portion of long-term debt – MEDC/MSF	116,000	654,000
Current portion of capital lease	8,000	20,000
Current portion of long-term debt - bank line of credit	1,546,000	2,147,000
Current portion of long-term debt - bank term loan	83,000	306,000
Total current liabilities	5,776,000	8,655,000
Long-term debt, capital lease	29,000	36,000
Warrant liability	178,000	409,000
Total liabilities	6,886,000	9,894,000
Class A Common Stock, $.001 par value, 100,000,000 authorized; December 26, 2014 – 37,381,413 shares issued and outstanding, March 31, 2014 – 31,203,213 shares issued and outstanding	37,000	31,000
Additional paid-in capital	61,712,000	58,752,000
Accumulated deficit	-49,813,000	-48,476,000
Total shareholders' equity	11,936,000	10,307,000
Total Liabilities and Shareholders’ Equity	18,822,000	20,201,000
Partners For Growth [Member]
Current liabilities:
Long-term Debt, Less Current Portion	365,000	794,000
Michigan Economic Development Corporation Loan Agreement [Member]
Current liabilities:
Long-term Debt, Less Current Portion	$538,000

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) (USD $)	Dec. 26, 2014	Mar. 31, 2014
Class A Common Stock, par value (in Dollars per share)	$0.00	$0.00
Class A Common Stock, authorized	100,000,000	100,000,000
Class A Common Stock, shares issued	37,381,413	31,203,213
Class A Common Stock, shares outstanding	37,381,413	31,203,213

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Dec. 26, 2014	Dec. 27, 2013	Dec. 26, 2014	Dec. 27, 2013
Sales, net	$5,805,000	$7,450,000	$21,257,000	$22,064,000
Cost of products sold	3,936,000	5,562,000	13,845,000	14,460,000
Gross profit	1,869,000	1,888,000	7,412,000	7,604,000
Operating expenses:
Research, development and engineering	959,000	1,164,000	3,019,000	3,890,000
Sales and marketing	535,000	640,000	1,682,000	1,867,000
General and administrative	928,000	1,135,000	3,291,000	3,461,000
Amortization expense	153,000	260,000	539,000	769,000
Total operating expenses	2,575,000	3,199,000	8,531,000	9,987,000
Loss from operations	-706,000	-1,311,000	-1,119,000	-2,383,000
Other income (expense):
Interest expense	-124,000	-153,000	-434,000	-478,000
Change in fair value of warrant liability	140,000	-124,000	231,000	-213,000
Other income (loss)	-11,000	-30,000	-15,000	-47,000
Total other expense	5,000	-307,000	-218,000	-738,000
Loss before benefit for income taxes	-701,000	-1,618,000	-1,337,000	-3,121,000
Benefit for income taxes	0	0	0	0
Net loss	($701,000)	($1,618,000)	($1,337,000)	($3,121,000)
Basic & diluted loss per share (in Dollars per share)	($0.02)	($0.05)	($0.04)	($0.10)
Weighted average common shares outstanding
Basic & diluted (in Shares)	37,381,000	31,243,000	35,860,000	31,223,000

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
	Dec. 26, 2014	Dec. 27, 2013
Cash flows from operating activities:
Net loss	($1,337,000)	($3,121,000)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	448,000	1,297,000
Amortization of intangible assets	539,000	769,000
Amortization of debt discount	107,000	143,000
Stock based compensation expense	52,000	110,000
Change in fair value of warrant liability	-231,000	213,000
Changes in operating assets and liabilities:
Accounts receivable – net	1,271,000	-389,000
Inventories	-238,000	-759,000
Prepaid expenses and other assets	-303,000	291,000
Accounts payable and accrued expenses	-1,505,000	1,186,000
Net cash used in operating activities	-1,197,000	-260,000
Cash flows from investing activities:
Capital expenditures	-198,000	-109,000
Proceeds from sale of equipment	125,000
Patent expenditures	-275,000	-176,000
Net cash used in investing activities	-348,000	-285,000
Cash flows from financing activities:
Payments on bank term loan	-223,000	-250,000
Net proceeds (payments) on bank line of credit	-601,000	1,128,000
Payments on MEDC/MSF term loans		-276,000
Payments on PFG term loan	-536,000	-537,000
Payments on capital lease	-19,000	-21,000
Net proceeds from issuance of Class A Common Stock	2,914,000
Taxes paid on net share settlement		-2,000
Net cash provided by financing activities	1,535,000	42,000
Net decrease in cash and cash equivalents	-10,000	-503,000
Cash and cash equivalents at beginning of period	120,000	619,000
Cash and cash equivalents at end of period	110,000	116,000
Supplemental disclosure of cash flow information:
Cash paid for interest	222,000	283,000
Supplemental disclosure of non-cash investing and financing activities:
Acquisition of equipment through capital lease		$82,000

Note_1_Basis_of_Presentation

Note 1 - Basis of Presentation	9 Months Ended
	Dec. 26, 2014
Disclosure Text Block [Abstract]
Business Description and Basis of Presentation [Text Block]	Note 1.   Basis of Presentation
	Business Description
	General – Advanced Photonix, Inc. ® (the Company, we, us, our, or API), was incorporated under the laws of the State of Delaware in June 1988. API is a leading test and measurement company that packages optoelectronic semiconductors into high-speed optical receivers (HSOR products), custom optoelectronic subsystems (Optosolutions products) and Terahertz (THz products) instrumentation, serving the test and measurement, telecommunications, military/aerospace and medical markets. The Company supports the customers from the initial concept and design phase of the product, through testing to full-scale production. The Company has two manufacturing facilities located in Camarillo, California and Ann Arbor, Michigan.
	The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and the Company’s wholly owned subsidiaries (Silicon Sensors Inc. Picometrix®, LLC, and Advanced Photonix Canada, Inc.). The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). All material inter-company accounts and transactions have been eliminated in consolidation. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments, consisting of normal and recurring adjustments, necessary for a fair presentation of the financial position and the results of operations for the periods presented have been included. Operating results for the nine-month period ended December 26, 2014 are not necessarily indicative of the results that may be expected for the balance of the fiscal year ending March 31, 2015.
	These unaudited condensed consolidated financial statements should be read in conjunction with Management’s Discussion and Analysis and the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2014, filed with the SEC on June 30, 2014.
	Recent Events- On January 30, 2015, the Company entered into a merger agreement with Luna Innovations Incorporated (trading on the NASDAQ under the symbol of LUNA) (“Luna”) and API Merger Sub (“Merger Sub”) pursuant to which Merger Sub will merge with and into API and API will become a wholly-owned subsidiary of Luna ("the Merger"). On the effective time of the merger, the existing stockholders of API will receive 0.31782 of a share of Luna common stock for each share of API’s Class A common stock owned by them. The closing of the transaction is subject the approval of the stockholders of each of Luna and API and other customary closing conditions. The Company anticipates the transaction to close by late spring or early summer 2015. The proposed merger is expected to provide API's shareholders the ability to realize the value added associated with a larger company and to execute the Company's growth plans over the near term.
	The merger agreement may be terminated by either Luna or API under certain circumstances, including if the merger has not been consummated on or before August 31, 2015, if the approval of the stockholders of either Luna or API is not obtained and for certain breaches of representations and warranties. If the merger agreement is terminated in certain specified circumstances, API must pay Luna, or Luna must pay API, as applicable, a termination fee of $750,000. In addition, if the merger agreement is terminated following a meeting of the stockholders of Luna or API at which the adoption of the merger agreement and approval of the transactions contemplated thereby, or the approval of the issuance of shares of Luna Common Stock to existing API stockholders as consideration for the merger is not approved, then Luna or API, as applicable, will be required to pay an amount up to $250,000 in reimbursement of the other party’s out-of-pocket expenses incurred in connection with the transaction.
	See Note 5 regarding recent modifications to the Company's debt facilities.
	Recent Accounting Pronouncements- In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09 – Revenue from Contracts with Customers (ASU 2014-09), which supersedes nearly all existing revenue recognition guidance under U.S. Generally Accepted Accounting Principles (U.S. GAAP). The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required with the revenue recognition process than are required under existing U.S. GAAP.
	The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company is currently evaluating the impact of adopting ASU 2014-09 on the consolidated financial statement and has not yet determined the method by which the Company will adopt the standard in fiscal 2018.
	In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern, which provides guidance on determining when and how to disclose going concern uncertainties in the financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern.
	ASU 2014-15 is effective for annual periods ending after December 15, 2016, and for interim periods within annual periods beginning after December 15, 2016. The Company is currently evaluating the impact of adopting ASU 2014-15 on the consolidated financial statement and has not yet determined the impact the standard may have on the fiscal 2017 disclosures.

Note_2_Stock_Based_Compensatio

Note 2 - Stock Based Compensation	9 Months Ended
	Dec. 26, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Note 2. Stock Based Compensation
	The Company has three stock equity plans: The 1997 Employee Stock Option Plan, the 2000 Stock Option Plan and the 2007 Equity Incentive Plan. As of December 26, 2014, no additional awards may be issued under either the 1997 Employee Stock Option Plan or the 2000 Stock Option Plan. There are 2,500,000 shares authorized for issuance under the 2007 Equity Incentive Plan, with 266,095 shares remaining available for future grant.
	Options and restricted stock awards may be granted to employees, officers, directors and consultants. Options typically vest over a period of one to four years and are exercisable up to ten years from the date of issuance. The option exercise price equals the stock’s market price on the date of grant. Restricted stock awards typically vest over a period of six months to four years, and the shares subject to such awards are generally not transferrable until the awards vest.
	The following table summarizes information regarding options outstanding and options exercisable at each of the quarterly periods through the nine months ended December 27, 2013 and December 26, 2014, respectively, and the changes during the periods then ended:
			Number of				Weighted Average Exercise Price per Share				Number of				Weighted Average Exercise Price per Share
			Options								Shares
			Outstanding								Exercisable
			(000’s)								(000’s)
	Balance as of March 31, 2013			2,392			$	1.66				2,142			$	1.76
	Granted			24			$	0.48
	Exercised			--			$	--
	Expired or forfeited			(114	)		$	1.03
	Balance as of June 28, 2013			2,302			$	1.68				2,099			$	1.76
	Granted			--			$	--
	Exercised			(4	)		$	0.44
	Expired or forfeited			(19	)		$	1.8
	Balance as of September 27, 2013			2,279			$	1.68				2,117			$	1.75
	Granted			--			$	--
	Exercised			--			$	--
	Expired or forfeited			(12	)		$	0.63
	Balance as of December 27, 2013			2,267			$	1.69				2,112			$	1.75
	Balance as of March 31, 2014			2,171			$	1.66				2,017			$	1.75
	Granted			--			$	--
	Exercised			--			$	--
	Expired or forfeited			(36	)		$	2.09
	Balance as of June 27, 2014			2,135			$	1.68				2,031			$	1.7
	Granted			--			$	--
	Exercised			--			$	--
	Expired or forfeited			(16	)		$	1.39
	Balance as of September 26, 2014			2,119			$	1.66				2,055			$	1.69
	Granted			--			$	--
	Exercised			--			$	--
	Expired or forfeited			(180	)		$	1.8
	Balance as of December 26, 2014			1,939			$	1.65				1,881			$	1.67
	Vested & expected to Vest, December 26, 2014			1,924			$	1.65
	Information regarding stock options outstanding as of December 26, 2014 is as follows:
					Options Outstanding
	Price Range				Shares				Weighted				Weighted
					(in 000s)				Average				Average
									Exercise				Remaining
									Price				Life
	$0.44	-	$1.25			521			$	0.71				6.75
	$1.26	-	$2.50			1,168			$	1.81				2.83
	$2.51	-	$5.34			250			$	2.83				0.67
					Options Exercisable
	Price Range				Shares				Weighted				Weighted
					(in 000s)				Average				Average
									Exercise				Remaining
									Price				Life
	$0.44	-	$1.25			463			$	0.69				6.7
	$1.26	-	$2.50			1,168			$	1.81				2.83
	$2.51	-	$5.34			250			$	2.83				0.67
	The intrinsic value of options exercised during each of the three and nine month periods ended December 26, 2014 was zero. The intrinsic value of options exercised during the three and nine month periods ended December 27, 2013 was zero and $600, respectively.
	During the third quarter of fiscal 2014, no restricted shares were issued. There were no restricted shares issued during the third quarter of fiscal 2015. The restricted share transactions are summarized below:
			Shares (000’s)				Weighted Average Grant Date
							Fair Value Per Share
	Unvested, March 31, 2013			128			$	0.87
	Granted			40			$	0.48
	Vested			--			$	--
	Expired or forfeited			(1	)		$	0.76
	Unvested, June 28, 2013			167			$	0.78
	Granted			50			$	0.66
	Vested			(26	)		$	0.89
	Expired or forfeited			(7	)		$	0.95
Unvested, September 27, 2013			184			$	0.72
Granted			--			$	--
Vested			(12	)		$	0.48
Expired or forfeited			(4	)		$	0.76
Unvested, December 27, 2013			168			$	0.74
		Shares (000’s)				Weighted Average Grant Date
						Fair Value Per Share
Unvested, March 31, 2014			84			$	0.76
Granted			--			$	--
Vested			--			$	--
Expired or forfeited			(16	)		$	0.5
Unvested, June 27, 2014			68			$	0.83
Granted			--			$	--
Vested			(25	)		$	0.95
Expired or forfeited			--			$	--
Unvested, September 26, 2014			43			$	0.75
Granted			--			$	--
Vested			--			$	--
Expired or forfeited			--			$	--
Unvested, December 26, 2014			43			$	0.75
The Company estimates the fair value of stock-based awards utilizing the Black-Scholes pricing model for stock options and using the intrinsic value for restricted stock. The fair value of the awards is amortized as compensation expense on a straight-line basis over the requisite service period of the award, which is generally the vesting period. The Black-Scholes fair value calculations involve significant judgments, assumptions, estimates and complexities that impact the amount of compensation expense to be recorded in current and future periods. The factors include:
	1	The time period that option awards are expected to remain outstanding has been determined based on the average of the original award period and the remaining vesting period. The expected term assumption for awards issued during the nine month periods ended December 27, 2013 was 6.3 years.
	2	The future volatility of the Company’s stock has been estimated based on the weekly stock price during the expected term to the date of the latest stock option grant. The expected volatility assumption for awards issued during the nine month periods ended December 27, 2013 averaged 68%.
	3	A dividend yield of zero has been assumed for awards issued during nine month periods ended December 27, 2013, based on the Company’s actual past experience and the fact that Company does not anticipate paying a dividend on its shares in the near future.
	4	The Company has based its risk-free interest rate assumption for awards issued during the nine month periods ended December 27, 2013 on the implied yield available on U.S. Treasury issues with an equivalent expected term, which averaged 1.1%.
	5	The forfeiture rate, for awards issued during the nine month periods ended December 26, 2014 and December 27, 2013, was 30% and 23%, respectively, and was based on the Company’s actual historical forfeiture history.
The Company’s stock-based compensation expense is classified in the table below:
		Three months ended								Nine months ended
		26-Dec-14				27-Dec-13				26-Dec-14				27-Dec-13
Cost of Products Sold		$	1,000			$	1,000			$	4,000			$	5,000
Research, development & engineering expense			3,000				4,000				10,000				16,000
General and Administrative expense			10,000				31,000				33,000				70,000
Sales and Marketing expense			1,000				4,000				5,000				19,000
Total Stock Based Compensation		$	15,000			$	40,000			$	52,000			$	110,000
At December 26, 2014, the total stock-based compensation expense related to unvested stock options and restricted shares granted to employees and independent directors under the Company’s stock option plans but not yet recognized was $33,000. This expense will be amortized on a straight-line basis over a weighted-average period of approximately 0.7 years and will be adjusted for subsequent changes in estimated forfeitures.

Note_3_Credit_Risk

Note 3 - Credit Risk	9 Months Ended
	Dec. 26, 2014
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	Note 3. Credit Risk
	Pervasiveness of Estimates and Risk - The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash equivalents and trade accounts receivable.
	Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. API has never experienced any losses related to these balances. At December 26, 2014, there was no cash held in excess of federally insured limits.
	Accounts receivable are unsecured and the Company is at risk to the extent such amounts become uncollectible. The Company performs periodic credit evaluations of its customers’ financial condition and generally does not require collateral. Any unanticipated change in the customers’ credit worthiness or other matters affecting the collectability of amounts due from such customers could have a material effect on the results of operations in the period in which such changes or events occur. As of December 26, 2014 one customer comprised 13% of accounts receivable. As of March 31, 2014, one customer individually comprised 19% of accounts receivable. The allowance for doubtful account balance was $28,000 on December 26, 2014 and $20,000 on March 31, 2014.

Note_4_Detail_of_Certain_Asset

Note 4 - Detail of Certain Asset Accounts	9 Months Ended
	Dec. 26, 2014
Details Of Certain Balance Sheet Accounts Disclosure [Abstract]
Details Of Certain Balance Sheet Accounts Disclosure [Text Block]	Note 4. Detail of Certain Asset Accounts
	Cash and Cash Equivalents - The Company considers all highly liquid investments, with an original maturity of three months or less when purchased, to be cash equivalents.
	Inventories - Inventories, which include material, labor and manufacturing overhead, are stated at the lower of cost (on a first in, first out method) or market. Inventories consist of the following at December 26, 2014 and March 31, 2014:
		26-Dec-14				March 31, 2014
	Raw material	$	3,031,000			$	3,093,000
	Work-in-process		848,000				954,000
	Finished products		1,108,000				702,000
	Inventories, net	$	4,987,000			$	4,749,000
	Slow moving and obsolete inventories are reviewed during the year to assess whether a cost adjustment is required. Our review of slow moving and obsolete inventory begins with a listing of all inventory items which have not moved regularly within the past 12 months. In addition, any residual inventory, which is customer specific and remaining on hand at the time of contract completion, is included in the list. The complete list of slow moving and obsolete inventory is then reviewed by the production, engineering and/or purchasing departments to identify items that can be utilized in the near future. These items are then excluded from the analysis and the remaining amount of slow-moving and obsolete inventory is then further assessed and a write down is recorded when warranted. Additionally, non-cancelable open purchase orders for parts we are obligated to purchase where demand has been reduced may also be reserved. Impairments for open purchase orders where the market price is lower than the purchase order price are also recorded. The impairments established for excess, slow moving, and obsolete inventory create a new cost basis for those items. The cost basis of these parts is not subsequently increased if the circumstances which led to the impairment change in the future. If a product that had previously been impaired is subsequently sold, the amount of reduced cost basis is reflected as cost of goods sold.
	Intangible Assets- Intangible assets that have definite lives consist of the following (dollars in thousands):
			Weighted Average		26-Dec-14
			Lives in		Amortization		Carrying			Accumulated			Intangibles
			Years		Method		Value			Amortization			Net
	Customer list		15		Straight Line		$	190		$	122		$	68
	Trademarks		15		Cash Flow			2,270			1,394			876
	Technology		10		Cash Flow			10,950			10,851			99
	Distribution Rights		7		Straight Line			148			39			109
	Patents pending							729			--			729
	Patents		10		Straight Line			1,449			652			797
	Total Intangibles						$	15,736		$	13,058		$	2,678
				Weighted Average		31-Mar-14
				Lives in		Amortization		Carrying			Accumulated			Intangibles
				Years		Method		Value			Amortization			Net
	Customer list			15		Straight Line		$	190		$	113		$	77
	Trademarks			15		Cash Flow			2,270			1,267			1,003
	Technology			10		Cash Flow			10,950			10,672			278
	Distribution Rights			7		Straight Line			148			23			125
	Patents pending								795			--			795
	Patents			10		Straight Line			1,108			444			664
	Total Intangibles							$	15,461		$	12,519		$	2,942
	Amortization expense for the three-month periods ended December 26, 2014 and December 27, 2013 was $153,000 and $260,000, respectively. The current patents held by the Company have remaining useful lives ranging from 2 years to 20 years. Amortization expense for the nine-month periods ended December 26, 2014 and December 27, 2013 was $539,000 and $769,000, respectively.
	The cash flow method of amortization is based upon management’s estimate of how the intangible asset contributes to our cash flows and best represents the pattern of how the economic benefits of the intangible asset will be consumed or used up. Such amortization is initially derived from the estimated undiscounted cash flows that were used in determining the original fair value of the intangible asset at the acquisition date and is monitored for significant changes in subsequent periods.
	Assuming no impairment to the intangible value, future amortization expense for intangible assets and patents, excluding patents pending, are as follows by fiscal year (in thousands):
	Intangible Assets and Patents
	Remainder of 2015	$	154
	2016		396
	2017		351
	2018		347
	2019		337
	2020 & after		364
	Total	$	1,949
	Patent pending costs of $729,000 are not included in the future amortization chart above. These costs will be amortized beginning the month the patents are granted.

Note_5_Debt

Note 5 - Debt	9 Months Ended
	Dec. 26, 2014
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 5. Debt
	Total outstanding debt of the Company as of December 26, 2014 and March 31, 2014 consisted of the following (in thousands):
		26-Dec-14		31-Mar-14
	Bank term loan	$	83	$	306
	Bank line of credit		1,546		2,147
	MEDC/MSF loans		654		654
	Partners for Growth (PFG) loan, net of debt discount		1,079		1,508
	Capital leases		37		56
	Total	$	3,399	$	4,671
	Bank Debt
	On January 31, 2012, API entered into a Loan and Security Agreement with Silicon Valley Bank (“SVB” and such agreement as amended from time to time, the “SVB Loan Agreement”) and a related Loan and Security Agreement (Ex-IM Loan Facility) with SVB (as amended from time to time, the “SVB Ex-Im Loan Agreement”, and together with the SVB Loan Agreement, the “SVB Loan Agreements”) that provided for a three-year $1 million term loan that expires in March 2015, and a $5 million line of credit with a $3 million export-import facility sublimit that expires in June 2016. Subsequent to the execution of the original SVB Loan Agreements, there have been ten amendments that have modified the financial covenants, allowed for the acquisition of substantially all of the operating assets of Silonex, Inc. (“Silonex”), allowed the Company to enter into the loan agreement with Partners for Growth III, L.P. (“PFG” and such agreement as amended from time to time as the “PFG Loan Agreement) as described below and extended the maturity date of the line of credit from January 2014 to June 2016.
	The SVB Loan Agreements as amended contained December 2013 and January 2014 financial covenants that required the Company to maintain a minimum liquidity ratio of 2.25 to 1.00 and a minimum trailing three month adjusted EBITDA, measured monthly of (1) a negative $300,000 for each fiscal month during the period July through October 2013; and (2) $1 for each fiscal month during the period November 2013 through February 2014.
	As of December 27, 2013 and January 24, 2014, the Company was not in compliance with the then existing minimum adjusted EBITDA covenant of $1 for the three months ended December 27, 2013 and January 31, 2014, respectively, and as of January 31, 2014, the Company was also not in compliance with the then existing minimum liquidity ratio of 2.25 to 1.00. In addition, the foregoing defaults triggered the cross-default provisions under each of the SVB Loan Agreements and the loan with PFG under the PFG Loan Agreement. Consequently, under the terms of each agreement, SVB and PFG were both entitled to proceed against the collateral provided as security for the loans issued thereunder upon an event of default subject, in PFG’s case, to any rights that SVB may have in that same collateral.
	On February 10, 2014, API entered into separate Forbearance Agreements with SVB and PFG pursuant to which and subject to certain exceptions, each of SVB and PFG agreed not to proceed against the collateral securing their respective loans until February 28, 2014. On March 5, 2014, the Company entered into separate amendment agreements with SVB and PFG where, among other things, (i) SVB agreed to extend the maturity date of the Company’s $5 million line of credit to May 31, 2014; (ii) the minimum trailing three month adjusted EBITDA covenant was reset to a negative $1.2 million for the fiscal month ended February 28, 2014, a negative $800,000 for the fiscal month ended March 31, 2014, a negative $600,000 for the fiscal month ended April 30, 2014 and a positive $1 for the fiscal month ending May 31, 2014; (iii) the existing minimum liquidity ratio covenant was reset to 1.30 to 1.00 as of February 28, 2014, and 2.25 to 1.00 for each month thereafter through May 2014; and (iv) each of SVB and PFG waived the existing defaults. In addition to the payment of an amendment fee, the Company agreed to pay each of SVB and PFG additional fees of up to $50,000 and $75,000, respectively, no later than May 31, 2014 (the “Tail Fees”).
	On April 30, 2014, API entered into separate amendment agreements with SVB and PFG where, among other things, (i) SVB agreed to extend the maturity date of the $5 million line of credit to July 31, 2014; (ii) the trailing three month adjusted EBITDA covenant was reset to a negative $800,000 for the fiscal month ended March 31, 2014, a negative $600,000 for the fiscal month ended April 30, 2014, a negative $250,000 for the fiscal months ending May 31, 2014 and June 30, 2014 and a positive $1 for the fiscal month ending July 31, 2014; and (iii) the existing minimum liquidity ratio covenant was reset to 1.30 to 1.00 as of March 31, 2014 through May 31, 2014, and 2.00 to 1.00 for each month thereafter through July 2014. In addition to the payment of an amendment fee, the Company agreed to pay each of SVB and PFG their respective Tail Fee and, commencing with the month ended May 31, 2014, an additional fee of $15,000 and $20,000, respectively, for each month that the liquidity ratio is less than 2.00 to 1.00 as of the last day of the month under measurement.
	On June 6, 2014, API received approximately $2,657,000 in proceeds before expenses from a secondary placement of 5,391,304 shares of Class A Common Stock through a firm underwriting by B Riley & Co., LLC. On June 10, 2014, the underwriter exercised the option on an additional 808,696 shares of Class A Common Stock for proceeds before expenses of $398,606. The net proceeds were used to pay down the existing line of credit with SVB and certain related fees. On June 20, 2014, API signed separate amendments with SVB and PFG where, among other things, (i) SVB agreed to extend the maturity date of the Company’s line of credit to June 2016, (ii) all parties agreed to a six month trailing adjusted EBTIDA covenant, measured at each fiscal month end, of negative $850,000 through June 2014, negative $300,000 for July through September 2014, a positive $1 for October through December 2014 and $100,000 each month thereafter subject to reset upon the submission of the fiscal 2016 budget but no lower than $100,000 on a rolling six month basis, (iii) all parties agreed to adjust the minimum liquidity ratio, as defined, to be 1.30 to 1.00 for months ending prior to June 2014 and 2.00 to 1.00 for all months on or after June 2014 as measured at each month end, and (iv) SVB restored an interest rate matrix based on the covenant performance that results in an interest rate on the line of credit to range from prime rate plus 50 basis points up to prime rate plus 400 basis points and an interest rate on the term loan to range from prime plus 100 basis points up to prime plus 450 basis points. The agreements confirmed the obligation to pay the previously agreed Tail Fees of $50,000 and $75,000 to SVB and PFG respectively, associated attorney fees for the amendment, but waived the added fees for May 2014 of $15,000 and $20,000 respectively.
	On November 10, 2014, API signed separate amendments to the SVB Loan Agreements and PFG Loan Agreements where, among other things, (i) all parties agreed to a six month trailing adjusted EBITDA covenant, measured at each fiscal month end, of negative $800,000 through March of 2015, negative $300,000 for April through June of 2015, and $100,000 each month thereafter, (ii) all parties agreed to adjust the minimum liquidity ratio, as defined, to be 2.00 to 1.00 through February of 2015 with a reduction to 1.50 to 1.00 for each month thereafter, and (iii) all parties agreed to continue the existing interest rate matrix. The amendments provided for a reimbursement of legal expenses and a modification fee of $10,000 with an additional $10,000 payable if the Company’s March 2015 quarterly adjusted EBITDA is less than one dollar.
	The interest rates on the SVB term loan and line of credit as of December 26, 2014 were 3.75% and 4.25%, respectively. The Company had approximately $1.5 million outstanding on the SVB line of credit with approximately $2.1 million in borrowing capacity as of December 26, 2014. However, given the liquidity covenant of 2.00 to 1.00 required by SVB, an additional advance in excess of $630,000 of the available line of credit would cause the Company to be in violation of the liquidity covenant with SVB.
	The EX-IM Loan Facility is guaranteed by the API’s subsidiaries and all borrowings under the SVB Loan Agreements are secured by a first priority security interest granted to SVB in substantially all of the Company’s respective assets.
	As of December 26, 2014, the Company is in compliance with the November 10, 2014 revisions to the liquidity and adjusted EBITDA covenants with SVB. The Company experienced a $2.1 million dollar reduction in HSOR revenues in the third quarter relative to the second quarter which was more than anticipated in the November 2014 covenant reset. As a result, the Company obtained further covenant relief on February 5, 2015 from SVB by reducing the rolling six month adjusted EBITDA requirement for January through June 2015 to a negative $1,250,000, $1 of adjusted EBITDA required in July 2015 and $100,000 each month thereafter until maturity with up to $150,000 in transaction costs carved out of the calculation. The parties also agreed to reduce the minimum liquidity ratio to 1.30 to 1.00 for January 2015 until the maturity of the line of credit. Pursuant to this tenth amendment, the interest rate was changed to prime plus 5% or 8.25% per annum for the line of credit. The Company is required to pay a $10,000 bank fee plus associated legal costs for the amendment with an added $15,000 payable upon the maturity or payoff of the line of credit. Should the Company experience a reduction in revenue or an increase in expenses from its most recent forecast which was the basis of the February 5, 2015 covenants, the loan would be callable creating a liquidity issue.
	Total interest payments made to the Company’s bank lenders during the nine months ended December 26, 2014 and December 27, 2013 were $63,000 and $57,000, respectively. Total interest payments made to the Company’s bank lenders during the three months ended December 26, 2014 and December 27, 2013 were $10,000 and $21,000, respectively.
	Partners for Growth Secured Debt
	On February 8, 2013, API entered into a $2.5 million secured Loan and Security Agreement with PFG that is subordinate to the SVB Loan Agreements. Pursuant to the terms of the PFG Agreement, the Company is obligated to make monthly principal payments of $59,524, plus accrued interest at 11.75% through maturity in August 2016. As part of the consideration for and as a closing condition to the PFG Loan Agreement, the Company agreed to grant PFG and certain of its affiliates warrants to purchase up to 1,195,000 shares of the Company’s Class A Common Stock (the “Warrants”) in a private placement pursuant to Section 4(a)(2) of the Securities Act. 995,000 of the shares issuable under the Warrants were granted at an initial strike price equal to $0.50 per share (the “Tier 1 Warrants”), and the remaining 200,000 shares issuable under the Warrants were granted at an initial strike price equal to $1.00 per share (“$1.00 Warrants”).
	The Warrants contain full-ratchet anti-dilution provisions that will result in proportional adjustments to the exercise price and the number of shares issuable under the PFG Warrant Agreements in the event that the Company conducts a stock split, subdivision, stock dividend or combination, or similar transaction. The PFG Warrant Agreements also include a net exercise provision pursuant to which warrant holders will receive the number of shares equal to (x) the product of (A) the number of Warrants exercised multiplied by (B) the difference between (1) the fair market value of a share of Class A Common Stock (with fair value generally being equal to the highest closing price of the Company’s Class A Common Stock during the 45 consecutive trading days prior to the date of exercise) and (2) the strike price of the Warrant, (y) divided by the fair market value of a share of Class A Common Stock. In addition, in the event the Company is acquired, liquidates, conducts a public offering, or the Warrants expire, each warrant holder will have the right to “put” its Warrants to the Company in exchange for a per share cash payment that varies with the number of shares issuable under each Warrant, but in the aggregate will not exceed $250,000.
	The PFG Loan Agreements as amended through December 2013 and January 2014, contained financial covenants that required the Company to maintain a minimum liquidity ratio of 2.25 to 1.00 and a minimum trailing three month adjusted EBITDA, measured monthly of (1) a negative $300,000 for each fiscal month during the period July through October 2013; and (2) $1 for each fiscal month during the period November 2013 through February 2014.
	As of December 27, 2013 and January 24, 2014, API was not in compliance with then existing adjusted minimum EBITDA covenant of $1 for the three months ended December 27, 2013 and January 24, 2014, respectively, and as of January 24, 2014, API was also not in compliance with the then existing minimum liquidity ratio of 2.25 to 1.00. In addition, the foregoing defaults triggered the cross-default provisions under each of the SVB Loan Agreements and the PFG Loan Agreement. Consequently, under the terms of each agreement, SVB and PFG were both entitled to proceed against the collateral provided as security for the loans issued thereunder upon an event of default subject, in PFG’s case, to any rights that SVB may have in that same collateral.
	On February 10, 2014, API entered into separate Forbearance Agreements with SVB and PFG pursuant to which and subject to certain exceptions, each of SVB and PFG agreed not to proceed against the collateral securing their respective loans until February 28, 2014. On March 5, 2014, the Company entered into separate amendment agreements with SVB and PFG where, among other things, the minimum trailing three month adjusted EBITDA covenant was reset to a negative $1.2 million for the fiscal month ended February 28, 2014, a negative $800,000 for the fiscal month ended March 31, 2014, a negative $600,000 for the fiscal month ended April 30, 2014 and a positive $1 for the fiscal month ending May 31, 2014; the existing minimum liquidity ratio covenant was reset to 1.30 to 1.00 as of February 28, 2014, and 2.25 to 1.00 for each month thereafter through May 2014; and each of SVB and PFG waived the existing defaults. In addition to the payment of an amendment fee, the Company agreed to pay each of SVB and PFG additional fees of up to $50,000 and $75,000, respectively, no later than May 31, 2014 (the “Tail Fees”).
	On April 30, 2014, API entered into separate amendment agreements with SVB and PFG where, among other things the trailing minimum three month adjusted EBITDA covenant was reset to a negative $800,000 for the fiscal month ended March 31, 2014, a negative $600,000 for the fiscal month ended April 30, 2014, a negative $250,000 for the fiscal months ending May 31, 2014 and June 30, 2014 and a positive $1 for the fiscal month ending July 31, 2014; and the existing minimum liquidity ratio covenant was reset to 1.30 to 1.00 as of March 31, 2014 through May 31, 2014, and 2.00 to 1.00 for each month thereafter through July 2014. In addition to the payment of an amendment fee, the Company agreed to pay each of SVB and PFG their respective Tail Fee and, commencing with the month ended May 31, 2014, an additional fee of $15,000 and $20,000, respectively, for each month that the liquidity ratio is less than 2.00 to 1.00 as of the last day of the month under measurement.
	On June 20, 2014, API signed separate amendments with SVB and PFG where, among other things, both parties agreed to a minimum six month trailing adjusted EBTIDA covenant, measured at each fiscal month end, of negative $850,000 through June 2014, negative $300,000 for July through September 2014, a positive $1 for October through December 2014 and $100,000 each month thereafter subject to reset upon the submission of the fiscal 2016 budget but no lower than $100,000 on a rolling six month basis, both parties agreed to adjust the minimum liquidity ratio, as defined, to be 1.30 to 1.00 for months ending prior to June 2014 and 2.00 to 1.00 for all months on or after June 2014 as measured at each month end. The agreements confirmed the obligation to pay the previously agreed Tail Fees of $50,000 and $75,000 to SVB and PFG respectively, associated attorney fees for the amendment, but waived the added fees for May of $15,000 for SVB and $20,000 for PFG.
	On November 10, 2014, API signed separate amendments to the Loan Agreements with SVB and PFG where, among other things, (i) all parties agreed to a six month trailing adjusted EBITDA covenant, measured at each fiscal month end, of negative $800,000 through March of 2015, negative $300,000 for April through June of 2015, and $100,000 each month thereafter, (ii) all parties agreed to adjust the minimum liquidity ratio, as defined, to be 2.00 to 1.00 through February of 2015 with a reduction to 1.50 to 1.00 for each month thereafter, and (iii) all parties agreed to continue the existing interest rate matrix. The amendments provided for a reimbursement of legal expenses and a modification fee of $12,500 with an additional $12,500 payable if the Company’s March 2015 quarterly adjusted EBITDA is less than one dollar.
	As of December 26, 2014, the Company is in compliance with the revised liquidity and adjusted EBITDA covenants with PFG, which were substantially the same as with SVB as of that date. The Company experienced a $2.1 million dollar reduction in HSOR revenues in the third quarter relative to the second quarter which was more than anticipated in the November 2014 covenant reset. As a result, the Company obtained further covenant relief on February 5, 2015 from PFG by reducing the rolling six month adjusted EBITDA requirement for January through June 2015 to a negative $1,250,000, $1 of adjusted EBITDA required in July 2015 and $100,000 each month thereafter until maturity with up to $150,000 in transaction costs carved out of the calculation. The parties also agreed to reduce the minimum liquidity ratio to 1.30 to 1.00 for January 2015 until the maturity of the term loan. Pursuant to the amendment, the interest rate remained at 11.75% per annum on the term loan. The Company is required to pay a $10,000 bank fee plus associated legal costs for the amendment with an added $15,000 payable upon the maturity or payoff of the term loan. Should the Company experience a reduction in revenue or an increase in expenses from its most recent forecast which was the basis of the February 5, 2015 covenants, the loan would be callable creating a liquidity issue.
	The Company determined the fair value of the warrant as of the issuance date to be $434,000. Pursuant to the accounting literature, a debt discount and a warrant liability were established as of the issuance date with the debt discount amortized over the life of the loan on an effective interest method. As of December 26, 2014, there was $112,000 in remaining unamortized debt discount offset against the PFG long term debt principal. See Note 6 to the Condensed Consolidated Financial Statements for additional information on the PFG warrants.
	Interest payments made to PFG during the three and nine month periods ended December 26, 2014 were $39,000 and $134,000, respectively. Interest payments made to PFG during the three and nine month periods ended December 27, 2013 were $60,000 and $198,000, respectively.
	MEDC/MSF Loans
	In fiscal years 2005 and 2006, we entered into two unsecured loan agreements that are currently held by the Michigan Economic Development Corporation (“MEDC” and such agreement the “MEDC Loan Agreement”) and a MEDC affiliate, the Michigan Strategic Fund (“MSF” and such agreement the “MSF Loan Agreement”) pursuant to which we borrowed an aggregate of amount of $2.2 million. As amended, payments on the approximately $654,000 in remaining principal outstanding in aggregate under the MEDC Loan Agreement and MSF Loan Agreement are deferred along with accrued interest at a rate of 6% per annum. Beginning on November 1, 2015 and for 11 months thereafter, the total principal and accrued interest are to be paid in monthly installments along with each month’s earned interest at a 6% per annum rate.
	Interest payments made to the MEDC/MSF were $22,000 and $25,000 during the 9 months ended December 26, 2014 and December 27, 2013, respectively. Interest payments made to the MEDC/MSF were $5,000 and $8,000 during both the three months ended December 26, 2014 and December 27, 2013, respectively.
	Capital Leases
	During fiscal 2014, the Company purchased $82,000 of equipment through several capital leases with monthly principal payments of $1,700 plus interest with some maturities extending to 2019. The leases are collateralized by the associated equipment.
	Interest payments made to the lessors for the three and nine months ended December 26, 2014 were $1,000 and $3,000, respectively. Interest payments made to the lessors for the three and nine months ended December 27, 2013 were $1,000 and $3,000, respectively.
	Prior to the closing of the Merger described in Note 1, and absent such a closing, the Company's near-term liquidity is dependent on it meeting its debt covenants- which management expects it to do based on current forecasts. However, if the merger is not approved by stockholders or does not proceed in a timely closing and projected revenue increases do not occur as forecast, then the Company may need to seek additional funding sources to meet its obligations which would include the alternatives of raising more capital, restructuring existing debt, or exploring strategic options which could include the sale of a portion or all of the Company. There can be no assurances that additional capital, if needed, will be available to the Company or the terms under which capital would be available to the Company. If adequate financing is not available, or is not available on favorable terms, the Company’s business, financial position and results of operations will be adversely affected.

Note_6_Stockholders_Equity

Note 6 - Stockholders' Equity	9 Months Ended
	Dec. 26, 2014
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 6. Stockholders’ Equity
	Warrants
	At December 26, 2014 and March 31, 2014, the Company had the following warrants outstanding and exercisable which could be exchanged into shares of Class A Common Stock:
		Shares (000’s)			Exercise Price
	2010 Warrants		267		$	1.242
	PFG Warrants		995		$	0.5
	PFG Warrants		200		$	1
	Total		1,462
	On November 29, 2010, the Company issued 267,196 warrants to Robin Risser and Steve Williamson (the 2010 Warrants). Each 2010 Warrant is exercisable over a five year period for one share of the Company’s Class A Common Stock at an exercise price subject to adjustment, based on a formula in the warrant agreements, if Common Stock is issued in the future below $1.404. Future adjustments cannot reduce the exercise price below $1.17. Given the issuance of the PFG Warrants in February 2013, a price reset was triggered to the 2010 Warrants and the new exercise price became $1.376. As a result of the exercise price reset feature, the fair values of the warrants are recorded as a liability with changes in values flowing through the Consolidated Statements of Operations.
	As described in Note 5, during February 2013, the Company issued warrants to PFG to purchase 1,195,000 shares of the Company’s Class A Common Stock. The PFG warrants are exercisable over a five year period with 995,000 shares at a strike price of $0.50 per share and another 200,000 shares with a strike price of $1.00 per share. The PFG warrant agreement contains a provision allowing the warrants to be put back to the Company under certain circumstances. Given this feature, the fair values of the warrants are recorded as a liability with changes in values flowing through the Consolidated Statements of Operations.
	For the three and nine months ended December 26, 2014, the Company recorded income of $140,000 and $231,000, respectively for the change in fair value of the warrant liability. For the three and nine months ended December 27, 2013, the Company recorded expense of $124,000 and $213,000 respectively. The fair value of the warrant liability outstanding was approximately $178,000 and $409,000 as of December 26, 2014 and March 31, 2014, respectively.
	The fair value of the warrant liability was estimated using the Monte Carlo option pricing model using the following assumptions:
		26-Dec-14						31-Mar-14
		PFG Warrants			2010 Warrants			PFG Warrants			2010 Warrants
	Contractual term in years		3.1			0.9			3.9			1.7
	Volatility		67.4	%		55.2	%		65.6	%		69.5	%
	Expected dividend		--			--			--			--
	Risk-free interest rate		1.21	%		0.23	%		1.25	%		0.34	%
	Expected volatility is based primarily on historical volatility using the weekly stock price for the most recent period equivalent to the term of the warrants. A dividend yield of zero has been assumed based on the Company’s actual past experience and the fact that the Company does not anticipate paying a dividend on its shares in the future. The Company has based its risk-free interest on the implied yield available on U.S. Treasury issues with equivalent contractual term.
	When a warrant may have different share exercise assumptions such as those issued in February 2013 to PFG and affiliates, the Company weighs various values based on the estimated probability of each outcome as of the valuation date.
	The following chart represents the activity in the Company’s Level 3 warrants during the nine months ended December 26, 2014 and the year ended March 31, 2014.
		Nine months Ended December 26, 2014			Year Ended
					31-Mar-14
	Level 3 Warrants, beginning of period	$	409,000		$	292,000
	Change in fair value of warrant liability		(231,000	)		117,000
	Level 3 Warrants, end of period	$	178,000		$	409,000
	MEDC Put Option
	In May 2010, the Company entered into a debt conversion agreement with the MEDC whereby the MEDC converted the accrued and unpaid interest as of November 30, 2009 totaling $562,336 into 1,041,363 unregistered shares of our Class A Common Stock at a price per share of $0.54 (market value of the stock on the day of conversion). In addition, the Company granted MEDC a put option to sell back the shares received pursuant to the debt conversion agreement in the event of a trigger event as defined in the debt conversion agreement. Given the conditions under which the put may be exercised are in the control of the Company, a liability for the fair value has not been recorded.

Note_7_Earnings_Per_Share

Note 7 - Earnings Per Share	9 Months Ended
	Dec. 26, 2014
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Note 7. Earnings Per Share
	The Company’s net earnings per share calculations are in accordance with FASB ASC 260-10. Accordingly, basic earnings (loss) per share are computed by dividing net earnings (loss) by the weighted average number of shares outstanding for each period. The calculation of loss per share is as follows:
		Three months ended
	Basic and Diluted	26-Dec-14			27-Dec-13
	Weighted Average Basic Shares Outstanding		37,381,000			31,243,000
	Dilutive effect of Stock Options and Warrants		--			--
	Weighted Average Diluted Shares Outstanding		37,381,000			31,243,000
	Net loss	$	(701,000	)	$	(1,618,000	)
	Basic and Diluted loss per share	$	(0.02	)	$	(0.05	)
		Nine months ended
	Basic and Diluted	26-Dec-14			27-Dec-13
	Weighted Average Basic Shares Outstanding		35,860,000			31,223,000
	Dilutive effect of Stock Options and Warrants		--			--
	Weighted Average Diluted Shares Outstanding		35,860,000			31,223,000
	Net loss	$	(1,337,000	)	$	(3,121,000	)
	Basic and Diluted loss per share	$	(0.04	)	$	(0.10	)
	The dilutive effect of stock options and warrants for each of the periods was not included in the calculation of diluted loss per share because to do so would have had an anti-dilutive effect as the Company had a net loss for the period.

Note_8_Fair_Value_of_Financial

Note 8 - Fair Value of Financial Instruments	9 Months Ended
	Dec. 26, 2014
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	Note 8. Fair Value of Financial Instruments
	The carrying value of all financial instruments potentially subject to valuation risk (principally consisting of cash equivalents, accounts receivable, and accounts payable) approximates the fair value based upon the short-term nature of these instruments. In the case of MEDC/MSF, PFG, and bank debt, the carrying value approximates fair value based upon prevailing interest rates available to the Company for debt of similar nature and maturity.

Note_9_Restructuring

Note 9 - Restructuring	9 Months Ended
	Dec. 26, 2014
Restructuring and Related Activities [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	Note 9. Restructuring
	During the quarter ended December 27, 2013, the Company made the decision to begin outsourcing the manufacturing of silicon photodiodes that are used in the Optosolutions production line to lower cost areas that were using larger production wafers. This opportunity became apparent with the acquisition and integration of the net assets of Silonex and we expect to save from $400,000 to $600,000 per year when fully implemented. To prepare for the transition, an inventory level was built up and the fabrication assets idled during the quarter ended December 27, 2013. API undertook a review of the alternative uses of the equipment and determined that an accelerated depreciation charge of approximately $608,000 was necessary in the quarter to state the net book value of the idled assets at amounts that could be obtained if the equipment was sold to independent third party buyers. Employees affected by the shutdown of this manufacturing activity were provided severance of approximately $59,000 of which $44,000 was accrued in the current quarter and $15,000 in the quarter ended September 27, 2013. The total restructuring costs of $652,000 and $667,000 are reflected in the cost of goods sold section of the Statement of Operations for the three months and nine months ended December 27, 2013.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	9 Months Ended
	Dec. 26, 2014
Accounting Policies [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements- In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09 – Revenue from Contracts with Customers (ASU 2014-09), which supersedes nearly all existing revenue recognition guidance under U.S. Generally Accepted Accounting Principles (U.S. GAAP). The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required with the revenue recognition process than are required under existing U.S. GAAP.
	The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company is currently evaluating the impact of adopting ASU 2014-09 on the consolidated financial statement and has not yet determined the method by which the Company will adopt the standard in fiscal 2018.
	In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern, which provides guidance on determining when and how to disclose going concern uncertainties in the financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern.
	ASU 2014-15 is effective for annual periods ending after December 15, 2016, and for interim periods within annual periods beginning after December 15, 2016. The Company is currently evaluating the impact of adopting ASU 2014-15 on the consolidated financial statement and has not yet determined the impact the standard may have on the fiscal 2017 disclosures.

Note_2_Stock_Based_Compensatio1

Note 2 - Stock Based Compensation (Tables)	9 Months Ended
	Dec. 26, 2014
Note 2 - Stock Based Compensation (Tables) [Line Items]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]			Number of				Weighted Average Exercise Price per Share				Number of				Weighted Average Exercise Price per Share
			Options								Shares
			Outstanding								Exercisable
			(000’s)								(000’s)
	Balance as of March 31, 2013			2,392			$	1.66				2,142			$	1.76
	Granted			24			$	0.48
	Exercised			--			$	--
	Expired or forfeited			(114	)		$	1.03
	Balance as of June 28, 2013			2,302			$	1.68				2,099			$	1.76
	Granted			--			$	--
	Exercised			(4	)		$	0.44
	Expired or forfeited			(19	)		$	1.8
	Balance as of September 27, 2013			2,279			$	1.68				2,117			$	1.75
	Granted			--			$	--
	Exercised			--			$	--
	Expired or forfeited			(12	)		$	0.63
	Balance as of December 27, 2013			2,267			$	1.69				2,112			$	1.75
	Balance as of March 31, 2014			2,171			$	1.66				2,017			$	1.75
	Granted			--			$	--
	Exercised			--			$	--
	Expired or forfeited			(36	)		$	2.09
	Balance as of June 27, 2014			2,135			$	1.68				2,031			$	1.7
	Granted			--			$	--
	Exercised			--			$	--
	Expired or forfeited			(16	)		$	1.39
	Balance as of September 26, 2014			2,119			$	1.66				2,055			$	1.69
	Granted			--			$	--
	Exercised			--			$	--
	Expired or forfeited			(180	)		$	1.8
	Balance as of December 26, 2014			1,939			$	1.65				1,881			$	1.67
	Vested & expected to Vest, December 26, 2014			1,924			$	1.65
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]					Options Outstanding
	Price Range				Shares				Weighted				Weighted
					(in 000s)				Average				Average
									Exercise				Remaining
									Price				Life
	$0.44	-	$1.25			521			$	0.71				6.75
	$1.26	-	$2.50			1,168			$	1.81				2.83
	$2.51	-	$5.34			250			$	2.83				0.67
					Options Exercisable
	Price Range				Shares				Weighted				Weighted
					(in 000s)				Average				Average
									Exercise				Remaining
									Price				Life
	$0.44	-	$1.25			463			$	0.69				6.7
	$1.26	-	$2.50			1,168			$	1.81				2.83
	$2.51	-	$5.34			250			$	2.83				0.67
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]			Three months ended								Nine months ended
			26-Dec-14				27-Dec-13				26-Dec-14				27-Dec-13
	Cost of Products Sold		$	1,000			$	1,000			$	4,000			$	5,000
	Research, development & engineering expense			3,000				4,000				10,000				16,000
	General and Administrative expense			10,000				31,000				33,000				70,000
	Sales and Marketing expense			1,000				4,000				5,000				19,000
	Total Stock Based Compensation		$	15,000			$	40,000			$	52,000			$	110,000
Restricted Stock [Member]
Note 2 - Stock Based Compensation (Tables) [Line Items]
Schedule of Nonvested Share Activity [Table Text Block]			Shares (000’s)				Weighted Average Grant Date
							Fair Value Per Share
	Unvested, March 31, 2013			128			$	0.87
	Granted			40			$	0.48
	Vested			--			$	--
	Expired or forfeited			(1	)		$	0.76
	Unvested, June 28, 2013			167			$	0.78
	Granted			50			$	0.66
	Vested			(26	)		$	0.89
	Expired or forfeited			(7	)		$	0.95
	Unvested, September 27, 2013			184			$	0.72
	Granted			--			$	--
	Vested			(12	)		$	0.48
	Expired or forfeited			(4	)		$	0.76
	Unvested, December 27, 2013			168			$	0.74
			Shares (000’s)				Weighted Average Grant Date
							Fair Value Per Share
	Unvested, March 31, 2014			84			$	0.76
	Granted			--			$	--
	Vested			--			$	--
	Expired or forfeited			(16	)		$	0.5
	Unvested, June 27, 2014			68			$	0.83
	Granted			--			$	--
	Vested			(25	)		$	0.95
	Expired or forfeited			--			$	--
	Unvested, September 26, 2014			43			$	0.75
	Granted			--			$	--
	Vested			--			$	--
	Expired or forfeited			--			$	--
	Unvested, December 26, 2014			43			$	0.75

Note_4_Detail_of_Certain_Asset1

Note 4 - Detail of Certain Asset Accounts (Tables)	9 Months Ended
	Dec. 26, 2014
Details Of Certain Balance Sheet Accounts Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]		26-Dec-14				March 31, 2014
	Raw material	$	3,031,000			$	3,093,000
	Work-in-process		848,000				954,000
	Finished products		1,108,000				702,000
	Inventories, net	$	4,987,000			$	4,749,000
Schedule of Finite-Lived Intangible Assets [Table Text Block]			Weighted Average		26-Dec-14
			Lives in		Amortization		Carrying			Accumulated			Intangibles
			Years		Method		Value			Amortization			Net
	Customer list		15		Straight Line		$	190		$	122		$	68
	Trademarks		15		Cash Flow			2,270			1,394			876
	Technology		10		Cash Flow			10,950			10,851			99
	Distribution Rights		7		Straight Line			148			39			109
	Patents pending							729			--			729
	Patents		10		Straight Line			1,449			652			797
	Total Intangibles						$	15,736		$	13,058		$	2,678
				Weighted Average		31-Mar-14
				Lives in		Amortization		Carrying			Accumulated			Intangibles
				Years		Method		Value			Amortization			Net
	Customer list			15		Straight Line		$	190		$	113		$	77
	Trademarks			15		Cash Flow			2,270			1,267			1,003
	Technology			10		Cash Flow			10,950			10,672			278
	Distribution Rights			7		Straight Line			148			23			125
	Patents pending								795			--			795
	Patents			10		Straight Line			1,108			444			664
	Total Intangibles							$	15,461		$	12,519		$	2,942
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Intangible Assets and Patents
	Remainder of 2015	$	154
	2016		396
	2017		351
	2018		347
	2019		337
	2020 & after		364
	Total	$	1,949

Note_5_Debt_Tables

Note 5 - Debt (Tables)	9 Months Ended
	Dec. 26, 2014
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]		26-Dec-14		31-Mar-14
	Bank term loan	$	83	$	306
	Bank line of credit		1,546		2,147
	MEDC/MSF loans		654		654
	Partners for Growth (PFG) loan, net of debt discount		1,079		1,508
	Capital leases		37		56
	Total	$	3,399	$	4,671

Note_6_Stockholders_Equity_Tab

Note 6 - Stockholders' Equity (Tables)	9 Months Ended
	Dec. 26, 2014
Stockholders' Equity Note [Abstract]
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]		Shares (000’s)			Exercise Price
	2010 Warrants		267		$	1.242
	PFG Warrants		995		$	0.5
	PFG Warrants		200		$	1
	Total		1,462
Fair Value, Option, Quantitative Disclosures [Table Text Block]		26-Dec-14						31-Mar-14
		PFG Warrants			2010 Warrants			PFG Warrants			2010 Warrants
	Contractual term in years		3.1			0.9			3.9			1.7
	Volatility		67.4	%		55.2	%		65.6	%		69.5	%
	Expected dividend		--			--			--			--
	Risk-free interest rate		1.21	%		0.23	%		1.25	%		0.34	%
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]		Nine months Ended December 26, 2014			Year Ended
					31-Mar-14
	Level 3 Warrants, beginning of period	$	409,000		$	292,000
	Change in fair value of warrant liability		(231,000	)		117,000
	Level 3 Warrants, end of period	$	178,000		$	409,000

Note_7_Earnings_Per_Share_Tabl

Note 7 - Earnings Per Share (Tables)	9 Months Ended
	Dec. 26, 2014
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]		Three months ended
	Basic and Diluted	26-Dec-14			27-Dec-13
	Weighted Average Basic Shares Outstanding		37,381,000			31,243,000
	Dilutive effect of Stock Options and Warrants		--			--
	Weighted Average Diluted Shares Outstanding		37,381,000			31,243,000
	Net loss	$	(701,000	)	$	(1,618,000	)
	Basic and Diluted loss per share	$	(0.02	)	$	(0.05	)
		Nine months ended
	Basic and Diluted	26-Dec-14			27-Dec-13
	Weighted Average Basic Shares Outstanding		35,860,000			31,223,000
	Dilutive effect of Stock Options and Warrants		--			--
	Weighted Average Diluted Shares Outstanding		35,860,000			31,223,000
	Net loss	$	(1,337,000	)	$	(3,121,000	)
	Basic and Diluted loss per share	$	(0.04	)	$	(0.10	)

Note_1_Basis_of_Presentation_D

Note 1 - Basis of Presentation (Details) (USD $)	9 Months Ended
	Dec. 26, 2014
Note 1 - Basis of Presentation (Details) [Line Items]
Number of Facilities	2
Luna Innovations Incorporated [Member]
Note 1 - Basis of Presentation (Details) [Line Items]
Common Stock Conversion	0.31782
Merger Agreement, Stated Termination Fee	750,000
Reimbursement of Other Party's Out-of-Pocket Expenses Incurred in Connection with Termination of Merger Agreement	250,000

Note_2_Stock_Based_Compensatio2

Note 2 - Stock Based Compensation (Details) (USD $)	3 Months Ended				9 Months Ended		3 Months Ended
	Dec. 26, 2014	Dec. 27, 2013	Sep. 27, 2013	Jun. 28, 2013	Dec. 26, 2014	Dec. 27, 2013	Sep. 25, 2015	Sep. 26, 2014
Note 2 - Stock Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value (in Dollars)	$0	$0			$0	$600
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares)			50,000	40,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)	$33,000				$33,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition					255 days
Employee Stock Option [Member] | Minimum [Member]
Note 2 - Stock Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period					1 year
Employee Stock Option [Member] | Maximum [Member]
Note 2 - Stock Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period					4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period					10 years
Employee Stock Option [Member]
Note 2 - Stock Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term						6 years 109 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate						68.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate						0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate						1.10%
Share Based Compensation Arrangement By Share Based PaymentAwardFairValueAssumptionsExpectedForfeitures					30.00%	23.00%
Restricted Stock [Member] | Minimum [Member]
Note 2 - Stock Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period					6 months
Restricted Stock [Member] | Maximum [Member]
Note 2 - Stock Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period					4 years
Restricted Stock [Member]
Note 2 - Stock Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares)							0	0
2007 Equity Incentive Plan [Member]
Note 2 - Stock Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)	2,500,000				2,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)	266,095				266,095

Note_2_Stock_Based_Compensatio3

Note 2 - Stock Based Compensation (Details) - Summary of Options Outstanding and Options Exercisable, Quarterly (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 26, 2014	Sep. 26, 2014	Jun. 27, 2014	Dec. 27, 2013	Sep. 27, 2013	Jun. 28, 2013
Summary of Options Outstanding and Options Exercisable, Quarterly [Abstract]
Balance, beginning	2,119	2,135	2,171	2,279	2,302	2,392
Balance, beginning	$1.66	$1.68	$1.66	$1.68	$1.68	$1.66
Balance,beginning	2,055	2,031	2,017	2,117	2,099	2,142
Balance, beginning	$1.69	$1.70	$1.75	$1.75	$1.76	$1.76
Balance, ending	1,939	2,119	2,135	2,267	2,279	2,302
Balance, ending	$1.65	$1.66	$1.68	$1.69	$1.68	$1.68
Balance, ending	1,881	2,055	2,031	2,112	2,117	2,099
Balance, ending	$1.67	$1.69	$1.70	$1.75	$1.75	$1.76
Vested & expected to Vest, December 26, 2014	1,924
Vested & expected to Vest, December 26, 2014	$1.65
Granted						24
Granted						$0.48
Exercised					-4
Exercised					$0.44
Expired or forfeited	-180	-16	-36	-12	-19	-114
Expired or forfeited	$1.80	$1.39	$2.09	$0.63	$1.80	$1.03

Note_2_Stock_Based_Compensatio4

Note 2 - Stock Based Compensation (Details) - Options Outstanding and Options Exercisable (USD $)	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 26, 2014
Range 1 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Price Range, Lower range	$0.44
Options Outstanding, Price Range, Upper range	$1.25
Options Outstanding, Shares (in Shares)	521
Options Outstanding, Weighted Average Exercise Price	$0.71
Options Outstanding, Weighted Average Remaining Life	6 years 9 months
Options Exercisable, Price Range, Lower range	$0.44
Options Exercisable, Price Range, Upper range	$1.25
Options Exercisable, Shares (in Shares)	463
Options Exercisable, Weighted Average Exercise Price	$0.69
Options Exercisable, Weighted Average Remaining Life	6 years 255 days
Range 2 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Price Range, Lower range	$1.26
Options Outstanding, Price Range, Upper range	$2.50
Options Outstanding, Shares (in Shares)	1,168
Options Outstanding, Weighted Average Exercise Price	$1.81
Options Outstanding, Weighted Average Remaining Life	2 years 302 days
Options Exercisable, Price Range, Lower range	$1.26
Options Exercisable, Price Range, Upper range	$2.50
Options Exercisable, Shares (in Shares)	1,168
Options Exercisable, Weighted Average Exercise Price	$1.81
Options Exercisable, Weighted Average Remaining Life	2 years 302 days
Range 3 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Price Range, Lower range	$2.51
Options Outstanding, Price Range, Upper range	$5.34
Options Outstanding, Shares (in Shares)	250
Options Outstanding, Weighted Average Exercise Price	$2.83
Options Outstanding, Weighted Average Remaining Life	244 days
Options Exercisable, Price Range, Lower range	$2.51
Options Exercisable, Price Range, Upper range	$5.34
Options Exercisable, Shares (in Shares)	250
Options Exercisable, Weighted Average Exercise Price	$2.83
Options Exercisable, Weighted Average Remaining Life	244 days

Note_2_Stock_Based_Compensatio5

Note 2 - Stock Based Compensation (Details) - Restricted Share Transactions (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 26, 2014	Jun. 27, 2014	Dec. 27, 2013	Sep. 27, 2013	Jun. 28, 2013	Dec. 26, 2014
Restricted Share Transactions [Abstract]
Unvested	68	84	184	167	128	43
Unvested	$0.83	$0.76	$0.72	$0.78	$0.87	$0.75
Unvested	43	68	168	184	167	43
Unvested	$0.75	$0.83	$0.74	$0.72	$0.78	$0.75
Granted				50	40
Granted				$0.66	$0.48
Vested	-25		-12	-26
Vested	$0.95		$0.48	$0.89
Expired or forfeited		-16	-4	-7	-1
Expired or forfeited		$0.50	$0.76	$0.95	$0.76

Note_2_Stock_Based_Compensatio6

Note 2 - Stock Based Compensation (Details) - Summary of Stock-based Compensation Expense (USD $)	3 Months Ended		9 Months Ended
	Dec. 26, 2014	Dec. 27, 2013	Dec. 26, 2014	Dec. 27, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation expense	$15,000	$40,000	$52,000	$110,000
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation expense	1,000	1,000	4,000	5,000
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation expense	3,000	4,000	10,000	16,000
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation expense	10,000	31,000	33,000	70,000
Selling and Marketing Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation expense	$1,000	$4,000	$5,000	$19,000

Note_3_Credit_Risk_Details

Note 3 - Credit Risk (Details) (USD $)	9 Months Ended	12 Months Ended
	Dec. 26, 2014	Mar. 31, 2014
Note 3 - Credit Risk (Details) [Line Items]
Cash, Uninsured Amount (in Dollars)	0
Allowance for Doubtful Accounts Receivable (in Dollars)	28,000	20,000
Accounts Receivable [Member] | Customer Concentration Risk [Member]
Note 3 - Credit Risk (Details) [Line Items]
Concentration Risk, Number of Customers	1	1
Concentration Risk, Percentage	13.00%	19.00%

Note_4_Detail_of_Certain_Asset2

Note 4 - Detail of Certain Asset Accounts (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 26, 2014	Dec. 27, 2013	Dec. 26, 2014	Dec. 27, 2013	Mar. 31, 2014
Note 4 - Detail of Certain Asset Accounts (Details) [Line Items]
Amortization of Intangible Assets	$153,000	$260,000	$539,000	$769,000
Finite-Lived Intangible Assets, Gross	15,736,000		15,736,000		15,461,000
Patents [Member] | Minimum [Member]
Note 4 - Detail of Certain Asset Accounts (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life			2 years
Patents [Member] | Maximum [Member]
Note 4 - Detail of Certain Asset Accounts (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life			20 years
Patents [Member]
Note 4 - Detail of Certain Asset Accounts (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life			10 years		10 years
Finite-Lived Intangible Assets, Gross	1,449,000		1,449,000		1,108,000
Other Intangible Assets [Member]
Note 4 - Detail of Certain Asset Accounts (Details) [Line Items]
Finite-Lived Intangible Assets, Gross	$729,000		$729,000		$795,000

Note_4_Detail_of_Certain_Asset3

Note 4 - Detail of Certain Asset Accounts (Details) - Inventories (USD $)	Dec. 26, 2014	Mar. 31, 2014
Inventories [Abstract]
Raw material	$3,031,000	$3,093,000
Work-in-process	848,000	954,000
Finished products	1,108,000	702,000
Inventories, net	$4,987,000	$4,749,000

Note_4_Detail_of_Certain_Asset4

Note 4 - Detail of Certain Asset Accounts (Details) - Intangible Assets (USD $)	9 Months Ended	12 Months Ended
	Dec. 26, 2014	Mar. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Carrying Value	$15,736,000	$15,461,000
Accumulated Amortization	13,058,000	12,519,000
Intangibles Net	2,678,000	2,942,000
Customer Lists [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted Average Lives in Years	15 years	15 years
Amortization Method	Straight Line	Straight Line
Carrying Value	190,000	190,000
Accumulated Amortization	122,000	113,000
Intangibles Net	68,000	77,000
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted Average Lives in Years	15 years	15 years
Amortization Method	Cash Flow	Cash Flow
Carrying Value	2,270,000	2,270,000
Accumulated Amortization	1,394,000	1,267,000
Intangibles Net	876,000	1,003,000
Unpatented Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted Average Lives in Years	10 years	10 years
Amortization Method	Cash Flow	Cash Flow
Carrying Value	10,950,000	10,950,000
Accumulated Amortization	10,851,000	10,672,000
Intangibles Net	99,000	278,000
Distribution Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted Average Lives in Years	7 years	7 years
Amortization Method	Straight Line	Straight Line
Carrying Value	148,000	148,000
Accumulated Amortization	39,000	23,000
Intangibles Net	109,000	125,000
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Carrying Value	729,000	795,000
Intangibles Net	729,000	795,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted Average Lives in Years	10 years	10 years
Amortization Method	Straight Line	Straight Line
Carrying Value	1,449,000	1,108,000
Accumulated Amortization	652,000	444,000
Intangibles Net	$797,000	$664,000

Note_4_Detail_of_Certain_Asset5

Note 4 - Detail of Certain Asset Accounts (Details) - Future Amortization Expenses (USD $)	Dec. 26, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Note 4 - Detail of Certain Asset Accounts (Details) - Future Amortization Expenses [Line Items]
Total	$2,678	$2,942
Excluding Patents Pending [Member]
Note 4 - Detail of Certain Asset Accounts (Details) - Future Amortization Expenses [Line Items]
Remainder of 2015	154
2016	396
2017	351
2018	347
2019	337
2020 & after	364
Total	$1,949

Note_5_Debt_Details

Note 5 - Debt (Details) (USD $)	1 Months Ended	9 Months Ended		0 Months Ended	1 Months Ended	0 Months Ended	1 Months Ended		3 Months Ended	0 Months Ended	3 Months Ended	0 Months Ended
	Jan. 31, 2012	Dec. 26, 2014	Dec. 27, 2013	Nov. 10, 2014	Jun. 20, 2014	Feb. 10, 2014	Apr. 30, 2014	Jan. 31, 2014	Dec. 27, 2013	Feb. 08, 2013	Dec. 26, 2014	Jun. 06, 2014	Jun. 10, 2014	Mar. 31, 2014	Feb. 28, 2013	Feb. 14, 2013	31-May-14	Dec. 31, 2006
Note 5 - Debt (Details) [Line Items]
Debt Instrument, Term	3 years
Loans Payable to Bank		$83,000									$83,000			$306,000
Proceeds from Issuance of Common Stock		2,914,000
Long-term Line of Credit		1,546,000									1,546,000			2,147,000
Debt Instrument, Interest Rate, Stated Percentage		6.00%									6.00%
Interest Paid		222,000	283,000
Unsecured Debt		654,000									654,000			654,000
Capital Lease Obligations Incurred			82,000
Period One [Member] | Silicon Valley Loan Agreement [Member]
Note 5 - Debt (Details) [Line Items]
Debt Instrument Covenant Annual Earnings Before Interest Taxes Depreciation and Amortization	-300,000	-1,250,000
Period One [Member] | SVB and PFG Agreements [Member]
Note 5 - Debt (Details) [Line Items]
Covenant Requirements Liquidity Ratio				2	1.3	1.3	1.3
Debt Instrument Covenant Annual Earnings Before Interest Taxes Depreciation and Amortization				-800,000	-850,000	-1,200,000	-800,000
Period One [Member] | Partners For Growth [Member]
Note 5 - Debt (Details) [Line Items]
Debt Instrument Covenant Annual Earnings Before Interest Taxes Depreciation and Amortization								-300,000
Period Two [Member] | Silicon Valley Loan Agreement [Member]
Note 5 - Debt (Details) [Line Items]
Debt Instrument Covenant Annual Earnings Before Interest Taxes Depreciation and Amortization	1	1
Period Two [Member] | SVB and PFG Agreements [Member]
Note 5 - Debt (Details) [Line Items]
Covenant Requirements Liquidity Ratio				1.5	2	2.25	2
Debt Instrument Covenant Annual Earnings Before Interest Taxes Depreciation and Amortization				-300,000	-300,000	-800,000	-600,000
Period Two [Member] | Partners For Growth [Member]
Note 5 - Debt (Details) [Line Items]
Debt Instrument Covenant Annual Earnings Before Interest Taxes Depreciation and Amortization								1
Period Three [Member] | Silicon Valley Loan Agreement [Member]
Note 5 - Debt (Details) [Line Items]
Debt Instrument Covenant Annual Earnings Before Interest Taxes Depreciation and Amortization		100,000
Period Three [Member] | SVB and PFG Agreements [Member]
Note 5 - Debt (Details) [Line Items]
Debt Instrument Covenant Annual Earnings Before Interest Taxes Depreciation and Amortization				-100,000	1	-600,000	-250,000
Period Four [Member] | SVB and PFG Agreements [Member]
Note 5 - Debt (Details) [Line Items]
Debt Instrument Covenant Annual Earnings Before Interest Taxes Depreciation and Amortization					100,000	1	1
Equipment [Member]
Note 5 - Debt (Details) [Line Items]
Capital Lease Obligations Incurred									82,000
Partners For Growth [Member] | Private Placement [Member]
Note 5 - Debt (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)										1,195,000					1,195,000
Partners For Growth [Member] | Maximum [Member]
Note 5 - Debt (Details) [Line Items]
Exercise Of Stock Warrants Value										250,000
Partners For Growth [Member]
Note 5 - Debt (Details) [Line Items]
Warrants and Rights Outstanding																434,000
Partners for Growth One [Member] | Private Placement [Member]
Note 5 - Debt (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)										995,000					995,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)										$0.50					0.5
Partners for Growth One [Member]
Note 5 - Debt (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		$0.50									$0.50
Partners for Growth Two [Member] | Private Placement [Member]
Note 5 - Debt (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)										200,000					200,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)										$1					1
Partners for Growth Two [Member]
Note 5 - Debt (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		$1									$1
Subsequent Event [Member] | EBITDA is Less than One Dollar [Member] | Partners For Growth [Member]
Note 5 - Debt (Details) [Line Items]
Legal Fees, Reimbursement				12,500
Subsequent Event [Member] | Partners For Growth [Member]
Note 5 - Debt (Details) [Line Items]
Legal Fees, Reimbursement				12,500
Fees Waived [Member] | Silicon Valley Loan Agreement [Member]
Note 5 - Debt (Details) [Line Items]
Debt Instrument, Covenant Requirement, Liquidity Ratio, Compliance Fees																	15,000
Fees Waived [Member] | Partners For Growth [Member]
Note 5 - Debt (Details) [Line Items]
Debt Instrument, Covenant Requirement, Liquidity Ratio, Compliance Fees																	20,000
EBITDA is Less than One Dollar [Member] | SVB and PFG Agreements [Member]
Note 5 - Debt (Details) [Line Items]
Legal Fees, Reimbursement				10,000
HSOR [Member] | Silicon Valley Loan Agreement [Member]
Note 5 - Debt (Details) [Line Items]
Revenue Increase (Decrease) In Current Period Comparing To Previous Period											2,100,000
Silicon Valley Loan Agreement [Member] | Loans Payable [Member]
Note 5 - Debt (Details) [Line Items]
Loans Payable to Bank	1,000,000
Silicon Valley Loan Agreement [Member] | Export Import Sublimit [Member]
Note 5 - Debt (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	3,000,000
Silicon Valley Loan Agreement [Member] | Line of Credit [Member] | Minimum [Member]
Note 5 - Debt (Details) [Line Items]
Debt Instrument Interest Additional Interest Above Prime Rate					0.50%
Silicon Valley Loan Agreement [Member] | Line of Credit [Member] | Maximum [Member]
Note 5 - Debt (Details) [Line Items]
Debt Instrument Interest Additional Interest Above Prime Rate					4.00%
Silicon Valley Loan Agreement [Member] | Line of Credit [Member] | Prime Rate [Member]
Note 5 - Debt (Details) [Line Items]
Debt Instrument, Basis Spread on Variable Rate		5.00%
Silicon Valley Loan Agreement [Member] | Line of Credit [Member]
Note 5 - Debt (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		630,000									630,000
Covenant Requirements Liquidity Ratio		2									2
Line of Credit Facility, Interest Rate at Period End		4.25%									4.25%
Long-term Line of Credit		1,500,000									1,500,000
Line of Credit Facility, Remaining Borrowing Capacity		2,100,000									2,100,000
Debt Instrument, Interest Rate, Stated Percentage		8.25%									8.25%
Silicon Valley Loan Agreement [Member] | Bank Term Loan [Member] | Minimum [Member]
Note 5 - Debt (Details) [Line Items]
Debt Instrument Interest Additional Interest Above Prime Rate					1.00%
Silicon Valley Loan Agreement [Member] | Bank Term Loan [Member] | Maximum [Member]
Note 5 - Debt (Details) [Line Items]
Debt Instrument Interest Additional Interest Above Prime Rate					4.50%
Silicon Valley Loan Agreement [Member] | Bank Term Loan [Member]
Note 5 - Debt (Details) [Line Items]
Debt Instrument, Interest Rate, Effective Percentage		3.75%									3.75%
Silicon Valley Loan Agreement [Member] | Line of Credit [Member]
Note 5 - Debt (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	5,000,000
Silicon Valley Loan Agreement [Member]
Note 5 - Debt (Details) [Line Items]
Covenant Requirements Liquidity Ratio	2.25
Debt Instrument, Fee Amount						50,000
Debt Instrument, Covenant Requirement, Liquidity Ratio, Compliance Fees							15,000
Transaction Costs		150,000
Bank Fee Required		10,000
Amendment Legal Fees		15,000
Interest Paid		63,000	57,000						21,000		10,000
SVB and PFG Agreements [Member] | Minimum [Member]
Note 5 - Debt (Details) [Line Items]
Covenant Requirements Liquidity Ratio							2
SVB and PFG Agreements [Member] | Line of Credit [Member]
Note 5 - Debt (Details) [Line Items]
Covenant Requirements Liquidity Ratio		1.3									1.3
SVB and PFG Agreements [Member]
Note 5 - Debt (Details) [Line Items]
Legal Fees, Reimbursement				10,000
Partners For Growth [Member]
Note 5 - Debt (Details) [Line Items]
Covenant Requirements Liquidity Ratio								2.25
Debt Instrument, Fee Amount						75,000
Debt Instrument, Covenant Requirement, Liquidity Ratio, Compliance Fees							20,000
Debt Instrument, Interest Rate, Stated Percentage										11.75%
Interest Paid		134,000	198,000						60,000		39,000
Debt Instrument, Face Amount										2,500,000
Debt Instrument, Periodic Payment, Principal										59,524
Minimum Trading Days For Calculating Closing Price of Common Stock										45 days
Debt Instrument, Unamortized Discount		112,000									112,000
Michigan Economic Development Corporation Loan Agreement [Member]
Note 5 - Debt (Details) [Line Items]
Interest Paid		22,000	25,000						8,000		5,000
Debt Instrument, Face Amount																		2,200,000
Unsecured Debt		654,000									654,000
Capital Lease Obligations [Member]
Note 5 - Debt (Details) [Line Items]
Interest Paid		3,000	3,000						1,000		1,000
Debt Instrument, Periodic Payment, Principal		1,700
Common Class A [Member]
Note 5 - Debt (Details) [Line Items]
Proceeds from Issuance of Common Stock												$2,657,000	$398,606
Stock Issued During Period, Shares, New Issues (in Shares)												5,391,304
Stock Issued During Period, Shares, Conversion of Units (in Shares)													808,696

Note_5_Debt_Details_Total_Outs

Note 5 - Debt (Details) - Total Outstanding Debt (USD $)	Dec. 26, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Total Outstanding Debt [Abstract]
Bank term loan	$83	$306
Bank line of credit	1,546	2,147
MEDC/MSF loans	654	654
Partners for Growth (PFG) loan, net of debt discount	1,079	1,508
Capital leases	37	56
Total	$3,399	$4,671

Note_6_Stockholders_Equity_Det

Note 6 - Stockholders' Equity (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended	1 Months Ended
	Dec. 26, 2014	Dec. 27, 2013	Dec. 26, 2014	Dec. 27, 2013	Mar. 31, 2014	Feb. 28, 2013	Nov. 29, 2010	31-May-10	Feb. 08, 2013
Note 6 - Stockholders' Equity (Details) [Line Items]
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net	$140,000	($124,000)	$231,000	($213,000)
Derivative Liability, Noncurrent	178,000		178,000		409,000
Warrant [Member] | 2010 Warrants [Member]
Note 6 - Stockholders' Equity (Details) [Line Items]
Fair Value Assumptions, Expected Dividend Rate			0.00%		0.00%
Warrant [Member] | Partners For Growth [Member]
Note 6 - Stockholders' Equity (Details) [Line Items]
Fair Value Assumptions, Expected Dividend Rate			0.00%		0.00%
Warrant [Member]
Note 6 - Stockholders' Equity (Details) [Line Items]
Fair Value Assumptions, Expected Dividend Rate			0.00%
Private Placement [Member] | Partners For Growth [Member]
Note 6 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)						1,195,000			1,195,000
Exercise Period Of Warrants						5 years
Private Placement [Member] | Partners for Growth One [Member]
Note 6 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)						995,000			995,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)						0.5			0.5
Private Placement [Member] | Partners for Growth Two [Member]
Note 6 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)						200,000			200,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)						1			1
2010 Warrants [Member] | Minimum [Member]
Note 6 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)							$1.17
2010 Warrants [Member]
Note 6 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)							267,196
Exercise Period Of Warrants							5 years
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in Shares)							1
Share Price Trigger (in Dollars per share)							$1.40
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$1.24		$1.24			1.376
Partners for Growth One [Member]
Note 6 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$0.50		$0.50
Partners for Growth Two [Member]
Note 6 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$1		$1
Michigan Economic Development Corporation Loan Agreement [Member]
Note 6 - Stockholders' Equity (Details) [Line Items]
Debt Conversion, Converted Instrument, Amount								$562,336
Debt Conversion, Converted Instrument, Shares Issued (in Shares)								1,041,363
Debt Instrument, Convertible, Conversion Price (in Dollars per share)								$0.54

Note_6_Stockholders_Equity_Det1

Note 6 - Stockholders' Equity (Details) - Warrants Outstanding and Exercisable (USD $)	Dec. 26, 2014	Feb. 28, 2013
In Thousands, except Per Share data, unless otherwise specified
Class of Warrant or Right [Line Items]
Warrants Outstanding and Exercisable	1,462
2010 Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding and Exercisable	267
Exercise Price (in Dollars per share)	$1.24	$1.38
Partners for Growth One [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding and Exercisable	995
Exercise Price (in Dollars per share)	$0.50
Partners for Growth Two [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding and Exercisable	200
Exercise Price (in Dollars per share)	$1

Note_6_Stockholders_Equity_Det2

Note 6 - Stockholders' Equity (Details) - Assumptions Used to Estimate Fair Value of Warrants (Warrant [Member])	9 Months Ended	12 Months Ended
	Dec. 26, 2014	Mar. 31, 2014
Fair Value, Option, Quantitative Disclosures [Line Items]
Expected dividend	0.00%
Partners For Growth [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Contractual term in years	3 years 36 days	3 years 328 days
Volatility	67.40%	65.60%
Expected dividend	0.00%	0.00%
Risk-free interest rate	1.21%	1.25%
2010 Warrants [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Contractual term in years	328 days	1 year 255 days
Volatility	55.20%	69.50%
Expected dividend	0.00%	0.00%
Risk-free interest rate	0.23%	0.34%

Note_6_Stockholders_Equity_Det3

Note 6 - Stockholders' Equity (Details) - Activity in Level Three Warrants (USD $)	9 Months Ended	12 Months Ended
	Dec. 26, 2014	Mar. 31, 2014
Activity in Level Three Warrants [Abstract]
Level 3 Warrants, beginning of period	$409,000	$292,000
Change in fair value of warrant liability	-231,000	117,000
Level 3 Warrants, end of period	$178,000	$409,000

Note_7_Earnings_Per_Share_Deta

Note 7 - Earnings Per Share (Details) - Calculation of Income (Loss) Per Share (USD $)	3 Months Ended		9 Months Ended
	Dec. 26, 2014	Dec. 27, 2013	Dec. 26, 2014	Dec. 27, 2013
Calculation of Income (Loss) Per Share [Abstract]
Weighted Average Basic Shares Outstanding	37,381,000	31,243,000	35,860,000	31,223,000
Dilutive effect of Stock Options and Warrants	0	0	0	0
Weighted Average Diluted Shares Outstanding	37,381,000	31,243,000	35,860,000	31,223,000
Net loss (in Dollars)	($701,000)	($1,618,000)	($1,337,000)	($3,121,000)
Basic and Diluted loss per share (in Dollars per share)	($0.02)	($0.05)	($0.04)	($0.10)

Note_9_Restructuring_Details

Note 9 - Restructuring (Details) (Outsourcing Manufacturing [Member], Silonex [Member], USD $)	3 Months Ended			9 Months Ended
	Dec. 26, 2014	Dec. 27, 2013	Sep. 27, 2013	Dec. 26, 2014	Dec. 27, 2013
Note 9 - Restructuring (Details) [Line Items]
Restructuring and Related Cost, Accelerated Depreciation	$608,000
Severance Costs	44,000		15,000	59,000
Restructuring Costs		652,000			667,000
Minimum [Member]
Note 9 - Restructuring (Details) [Line Items]
Business Acquisition Costs Savings		400,000
Maximum [Member]
Note 9 - Restructuring (Details) [Line Items]
Business Acquisition Costs Savings		$600,000